Q&A: Lil­ly sci­ence chief Dan Skovron­sky talks deal­mak­ing, AI and con­sis­tent in­vest­ing

Eli Lil­ly is on a hot streak. It’s about to find out whether its di­a­betes drug can al­so be mar­ket­ed for weight man­age­ment. Its Alzheimer’s dis­ease ther­a­py is al­so ex­pect­ed to get a de­ci­sion from the FDA by the end of the year. And it’s been steadi­ly ink­ing deals — five ac­qui­si­tions in as many months (with hints of a few that are still un­der wraps).

End­points News spoke with Lil­ly’s mul­ti-hy­phen­at­ed ex­ec­u­tive Dan Skovron­sky about Lil­ly’s M&A plans, play­ing the long game in drug de­vel­op­ment and why it doesn’t need mega deals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER